Inflamm-aging, cytokines and aging: State of the art, new hypotheses on the role of mitochondria and new perspectives from systems biology

Current Pharmaceutical Design

Volumn 12, Issue 24, 2006, Pages 3161-3171

  Salvioli, Stefano ^a,b   Capri, M ^a   Valensin, S ^a,b   Tieri, P ^a,b   Monti, D ^c   Ottaviani, E ^d   Franceschi, C ^a,b,e  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Bioinformatics and Biocomplexity 'L Galvani' (CIG)   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^e INRCA   (Italy)

Author keywords

Aging; Bioinformatics; Cytokines; Genetic polymorphisms; Inflammation; Mitochondria; Systems biology

Indexed keywords

ACTIVIN; ALANINE; APOLIPOPROTEIN E4; ASPARTIC ACID; BONE MORPHOGENETIC PROTEIN; C REACTIVE PROTEIN; CYTOKINE; GLYCINE; HEAT SHOCK PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PROLINE; REACTIVE OXYGEN METABOLITE; SERUM AMYLOID A; SOMATOMEDIN C; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

AGED; AGING; ALZHEIMER DISEASE; ARTHRITIS; ATHEROSCLEROSIS; BIOINFORMATICS; CAENORHABDITIS ELEGANS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMPUTER MODEL; DISEASE ASSOCIATION; ENERGY METABOLISM; GENETIC ANALYSIS; GENETIC POLYMORPHISM; HEALTH STATUS; HUMAN; HYPOTHESIS; IMMUNE RESPONSE; INFECTION SENSITIVITY; INFLAMMATION; INNATE IMMUNITY; LONGEVITY; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; MITOCHONDRION; MOUSE; MUSCLE ATROPHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOARTHRITIS; OXIDATIVE STRESS; PHYLOGENY; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; SACCHAROMYCES CEREVISIAE; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMS BIOLOGY; TELEOST;

AGING; ANIMALS; CYTOKINES; HUMANS; INFLAMMATION; MITOCHONDRIA; PHYLOGENY; POLYMORPHISM, GENETIC; SYSTEMS BIOLOGY;

EID: 33747172229     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206777947470     Document Type: Review

References (99)

1. Fagiolo U, Cossarizza A, Scala E, Fanales-Belasio E, Ortolani C, Cozzi E, et al. Increased cytokine production in mononuclear cells of healthy elderly people. Eur J Immunol 1993; 23: 2375-8.
2. Di Iorio A, Ferrucci L, Sparvieri E, Cherubini A, Volpato S, Corsi A, et al. Serum IL-1beta levels in health and disease: a population-based study. 'The InCHIANTI study'. Cytokine 2003; 22: 198-205.
3. Gerli R, Monti D, Bistoni O, Mazzone AM, Peri G, Cossarizza A, et al. Chemokines, sTNF-Rs and sCD30 serum levels in healthy aged people and centenarians. Mech Ageing Dev 2000; 121: 37-46.
4. Wei J, Xu H, Davies JL, Hemmings GP. Increase of plasma IL-6 concentration with age in healthy subjects. Life Sci 1992; 51: 1953-6.
5. Ershler WB, Sun WH, Binkley N, Gravenstein S, Volk MJ, Kamoske G, et al. Interleukin-6 and aging: blood levels and mononuclear cell production increase with advancing age and in vitro production is modifiable by dietary restriction. Lymphokine Cytokine Res 1993; 12: 225-30.
6. Bruunsgaard H, Andersen-Ranberg K, Jenne B, Pedersen AN, Skinhoj P, Pedersen BK. A high plasma concentration of TNF-alpha is associated with dementia in centenarians. J Gerontol A Biol Sci Med Sci 1999; 54: M357-64.
7. Caswell M, Pike LA, Bull BS, Stuart J. Effect of patient age on tests of the acute-phase response. Arch Pathol Lab Med 1993; 117: 906-10.
8. Ballou SP, Lozanski FB, Hodder S, Rzewnicki DL, Mion LC, Sipe JD, et al. Quantitative and qualitative alterations of acute-phase proteins in healthy elderly persons. Age Ageing 1996; 25: 224-30.
9. Ferrucci L, Harris TB, Guralnik JM, Tracy RP, Corti MC, Cohen HJ, et al. Serum IL-6 level and the development of disability in older persons J Am Geriatr Soc 1999; 47: 639-46.
10. Cesari M, Penninx BW, Pahor M, Lauretani F, Corsi AM, Rhys Williams G, et al. Inflammatory markers and physical performance in older persons: the InCHIANTI study. J Gerontol A Biol Sci Med Sci 2004; 59: 242-8.
11. Barbieri M, Ferrucci L, Corsi AM, Macchi C, Lauretani F, Bonafe M, et al. Is chronic inflammation a determinant of blood pressure in the elderly? Am J Hypertens 2003; 16: 537-43.
12. Bruunsgaard H, Ladelund S, Pedersen AN, Schroll M, Jorgensen T, Pedersen BK. Predicting death from tumour necrosis factor-alpha and interleukin-6 in 80-year-old people. Clin Exp Immunol 2003; 132: 24-31.
13. Bruunsgaard H, Andersen-Ranberg K, Hjelmborg JB, Pedersen BK, Jeune B. Elevated levels of tumor necrosis factor alpha and mortality in centenarians. Am J Med 2003; 115: 278-83.
14. Carrieri G, Marzi E, Olivieri F, Marchegiani F, Cavallone L, Cardelli M, et al. The G/C915 polymorphism of transforming growth factor beta1 is associated with human longevity: a study in Italian centenarians. Aging Cell 2004; 3: 443-8.
15. Lio D, Scola L, Crivello A, Colonna-Romano G, Candore G, Bonafe M, et al. Gender-specific association between -1082 IL-10 promoter polymorphism and longevity. Genes Immun 2002; 3: 30-3.
16. Lio D, Licastro F, Scola L, Chiappelli M, Grimaldi LM, Crivello A, et al. Interleukin-10 promoter polymorphism in sporadic Alzheimer's disease. Genes Immun 2003; 4: 234-8.
17. Baggio G, Donazzan S, Monti D, Mari D, Martini S, Gabelli C, et al. Lipoprotein(a) and lipoprotein profile in healthy centenarians: a reappraisal of vascular risk factors. FASEB J 1998; 12: 433-7.
18. Franceschi C, Bonafe M, Valensin S, Olivieri F, De Luca M, Ottaviani E, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci 2000; 908: 244-54.
19. Franceschi C, Bonafe M. Centenarians as a model for healthy aging. Biochem Soc Trans 2003; 31: 457-61.
20. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 10: 1369-76.
21. Terry CF, Loukaci V, Green FR. Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem 2000; 275: 18138-44.
22. Suarez A, Castro P, Alonso R, Mozo L, Gutierrez C. Interindividual variations in constitutive interleukin-10 messenger RNA and protein levels and their association with genetic polymorphisms. Transplantation 2003; 75: 711-7.
23. Bonafe M, Olivieri F, Cavallone L, Giovagnetti S, Mayegiani F, Cardelli M, et al. A gender--dependent genetic predisposition to produce high levels of IL-6 is detrimental for longevity. Eur J Immunol 2001; 31: 2357-61.
24. Rea IM, Ross OA, Armstrong M, McNerlan S, Alexander DH, Curran MD, et al. Interleukin-6-gene C/G 174 polymorphism in nonagenarian and octogenarian subjects in the BELFAST study. Reciprocal effects on IL-6, soluble IL-6 receptor and for IL-10 in serum and monocyte supernatants. Mech Ageing Dev 2003; 124: 555-61.
25. Cipriano C, Caruso C, Lio D, Giacconi R, Malavolta M, Muti E, et al. The -308G/A polymorphism of TNF-alpha influences immunological parameters in old subjects affected by infectious diseases. Int J Immunogenet 2005; 32: 13-8.
26. Franceschi C, Motta L, Valensin S, Rapisarda R, Franzone A, Berardelli M, et al. Do men and women follow different trajectories to reach extreme longevity? Italian Multicenter Study on Centenarians (IMUSCE). Aging (Milano) 2000; 12: 77-84.
27. Evert J, Lawler E, Bogan H, Perls T. Morbidity profiles of centenarians: survivors, delayers, and escapers. J Gerontol A Biol Sci Med Sci 2003; 58: 232-7.
28. Lio D, Scola L, Crivello A, Colonna-Romano G, Candore G, Bonafe M, et al. Inflammation, genetics, and longevity: further studies on the protective effects in men of IL-10 -1082 promoter SNP and its interaction with TNF-alpha -308 promoter SNP. J Med Genet 2003; 40: 296-9.
29. Lio D, Candore G, Crivello A, Scola L, Colonna-Romano G, Cavallone L, et al. Opposite effects of interleukin 10 common gene polymorphisms in cardiovascular diseases and in successful ageing: genetic background of male centenarians is protective against coronary heart disease. J Med Genet 2004; 41: 790-4.
30. Barbieri M, Bonafe M, Rizzo MR, Ragno E, Olivieri F, Marchegiani F, et al. Gender specific association of genetic variation in peroxisome proliferator-activated receptor (PPAR)gamma-2 with longevity. Exp Gerontol 2004; 39: 1095-100.
31. Harada T, Terakawa N. Cytokines in peritoneal fluid from women with active endometriosis. In: Minaguchi H, Sugimoto O Eds, Endometriosis today. New York, Parthenon 1997; 144-8
32. Westendorp RG, van Dunne FM, Kirkwood TB, Helmerhorst FM, Huizinga TW. Optimizing human fertility and survival. Nat Med 2001; 7: 873.
33. Harada T, Iwabe T, Terakawa N. Role of cytokines in endometriosis. Fertil Steril. 2001; 76: 1-10.
34. de Groot CJ, Jansen MW, Bertina RM, Schonkeren JJ, Helmerhorst FM, Huizinga TW. Interleukin 10-2849AA genotype protects against pre-eclampsia. Genes Immun 2004; 5: 313-4.
35. Wisniewski HG, Vilcek J. Cytokine-induced gene expression at the crossroads of innate immunity, inflammation and fertility: TSG-6 and PTX3/TSG-14. Cytokine Growth Factor Rev 2004; 15: 129-46.
36. Williams GC. Pleiotropy, natural selection, and the evolution of senescence. Evolution 1957; 11: 398-411.
37. Leroi AM, Bartke A, Benedictis GD, Franceschi C, Gartner A, Gonos E, et al. What evidence is there for the existence of individual genes with antagonistic pleiotropic effects? Mech Ageing Dev 2005; 126: 421-9.
38. Arbabi S, Maier RV. Mitogen-activated protein kinases. Crit Care Med 2002; 30: S74-9.
39. Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000; 25: 187-91.
40. Werner M, Topp R, Wimmer K, Richter K, Bischof W, Wjst M, et al. TLR4 gene variants modify endotoxin effects on asthma. J Allergy Clin Immunol 2003; 112: 323-30.
41. Agnese DM, Calvano JE, Hahm SJ, Coyle SM, Corbett SA, Calvano SE, et al. Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. J Infect Dis 2002; 186: 1522-5.
42. Lorenz E, Mira JP, Frees KL, Schwartz DA. Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch Intern Med 2002; 162: 1028-32.
43. Child NJ, Yang IA, Pulletz MC, de Courcy-Golder K, Andrews AL, Pappachan VJ, et al. Polymorphisms in Toll-like receptor 4 and the systemic inflammatory response syndrome. Biochem Soc Trans 2003; 31: 652-3.
44. Kiechl S, Lorenz E, Reindl M, Wiedermann CJ, Oberhollenzer F, Bonora E, et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002; 347: 185-92.
45. Kolek MJ, Carlquist JF, Muhlestein JB, Whiting BM, Horne BD, Bair TL, et al. Toll-like receptor 4 gene Asp299Gly polymorphism is associated with reductionsin vascular inflammation, angiographic coronary artery disease, and clinical diabetes. Am Heart J 2004; 148: 1034-40.
46. Edfeldt K, Bennet AM, Eriksson P, Frostegard J, Wiman B, Hamsten A, et al. Association of hypo-responsive toll-like receptor 4 variants with risk of myocardial infarction. Eur Heart J 2004; 25: 1447-53.
47. Balistreri CR, Candore G, Colonna-Romano G, Lio D, Caruso M, Hoffmann E, et al. Role of Toll-like receptor 4 in acute myocardial infarction and longevity. JAMA 2004; 292: 2339-40.
48. Lorenz E, Frees KL, Schwartz DA. Determination of the TLR4 genotype using allele-specific PCR. Biotechniques 2001; 31: 22-4.
49. Ohashi K, Burkart V, Flohe S, Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol 2000; 164: 558-61.
50. Asea A, Kraeft SK, Kurt-Jones EA, Stevenson MA, Chen LB, Finberg RW, et al. HSP70 stimulates cytokine production through a CD14 dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat Med 2000; 6: 435-42.
51. Moroi Y, Mayhew M, Trcka J, Hoe MH, Takechi Y, Hartl FU, et al. Induction of cellular immunity by immunization with novel hybrid peptides complexed to heat shock protein 70. Proc Natl Acad Sci USA 2000; 97: 3485-90.
52. Asea A, Rehli M, Kabingu E, Boch JA, Bare O, Auron PE, et al. Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4. J Biol Chem 2002; 277: 15028-34.
53. Terry DF, Wilcox MA, McCormick MA, Perls TT. Cardiovascular disease delay in centenarian offspring. J Gerontol A Biol Sci Med Sci 2004; 59: 385-9.
54. Rea IM, McNerlan S, Pockley AG. Serum heat shock protein and anti-heat shock protein antibody levels in aging. Exp Gerontol 2001; 36: 341-52.
55. Abravaya K, Phillips B, Morimoto RI. Heat shock-induced interactions of heat shock transcription factor and the human hsp70 promoter examined by in vivo footprinting. Mol Cell Biol 1991; 11: 586-92.
56. Altomare K, Greco V, Bellizzi D, Berardelli M, Dato S, DeRango F, et al. The allele (A)(-110) in the promoter region of the HSP70-1 gene is unfavorable to longevity in women. Biogerontology 2003; 4: 215-20.
57. Marini M, Lapalombella R, Canaider S, Farina A, Monti D, De Vescovi V, et al. Heat shock response by EBV-immortalized B-lymphocytes from centenarians and control subjects: a model to study the relevance of stress response in longevity. Exp Gerontol 2004; 39: 83-90.
58. Franceschi C, Olivieri F, Marchegiani F, Cardelli M, Cavallone L, Capri M, et al. Genes involved in immune response/inflammation, IGF1/insulin pathway and response to oxidative stress play a major role in the genetics of human longevity: the lesson of centenarians. Mech Ageing Dev 2005; 126: 351-61.
59. Bonafe M, Barbieri M, Marchegiani F, Olivieri F, Ragno E, Giampieri C, et al. Polymorphic variants of insulin-like growth factor I (IGF-1) receptor and phosphoinositide 3-kinase genes affect IGF-I plasma levels and human longevity: cues for an evolutionarily conserved mechanism of life span control. J Clin Endocrinol Metab 2003; 88: 3299-304.
60. Cappola AR, Xue QL, Ferrucci L, Guralnik JM, Volpato S, Fried LP. Insulin-like growth factor I and interleukin-6 contribute synergistically to disability and mortality in older women. J Clin Endocrinol Metab 2003; 88: 2019-25.
61. Barbieri M, Ferrucci L, Ragno E, Corsi A, Bandinelli S, Bonafe M, et al. Chronic inflammation and the effect of IGF-I on muscle strength and power in older persons. Am J Physiol Endocrinol Metab 2003; 284: E481-7.
62. Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S. Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol 2005; 288: H2031-41.
63. Blanquart C, Barbier O, Fruchart JC, Staels B, Glineur C. Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation. J Steroid Biochem Mol Biol 2003; 85: 267-73.
64. Ziouzenkova O, Plutzky J. Lipolytic PPAR activation: new insights into the intersection of triglycerides and inflammation? Curr Opin Clin Nutr Metab Care 2004; 7: 369-75.
65. Abraham, E. Nuclear factor-B and its role in sepsis-associated organ failure. J Infect Dis 2003; 187: S364-9.
66. Chung HY, Kim HJ, Kim KW, Choi JS, Yu BP. Molecular inflammation hypothesis of aging based on the anti-aging mechanism of calorie restriction. Microsc Res Tech 2002; 59: 264-72.
67. Robbesyn F, Salvayre R, Negre-Salvayre A. Dual role of oxidized LDL on the NF-kappaB signaling pathway. Free Radic Res 2004; 38: 541-51.
68. Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol 1956; 11: 298-300.
69. Torroni A, Huoponen K, Francalacci P, Petrozzi M, Morelli L, Scozzari R, et al. Classification of European mtDNAs from an analysis of three European populations. Genetics 1996; 144: 1835-50.
70. Ruiz-Pesini E, Lapena AC, Diez-Sanchez C, Perez-Martos A, Montoya J, Alvarez E, et al. Human mtDNA haplogroups associated with high or reduced spermatozoa motility. Am J Hum Genet 2000; 67: 682-96.
71. De Benedictis G, Rose G, Carrieri G, De Luca M, Falcone E, Passarino G, et al. Mitochondrial DNA inherited variants are associated with successful aging andlongevity in humans. FASEB J 1999; 13: 1532-6.
72. Carrieri G, Bonafe M, De Luca M, Rose G, Varcasia O, Bruni A, et al. Mitochondrial DNA haplogroups and APOE4 allele are non-independent variables in sporadic Alzheimer's disease. Hum Genet 2001; 108: 194-8.
73. Krabbe KS, Pedersen M, Bruunsgaard H. Inflammatory mediators in the elderly. Exp Gerontol 2004; 39: 687-99.
74. Tauber AI. The immune self. Theory or metaphor? Cambridge University press, 1997
75. Ottaviani E, Malagoli D, Franchini A. Invertebrate humoral factors: cytokines as mediators of cell survival. Prog Mol Subcell Biol 2004; 34: 1-25.
76. Beck G. Macrokines:invertebrate cytokine-like molecules? Front Biosci 1998; 3: d559-69.
77. Franchini A, Perruzi E, Ottaviani E. Morphochemical age-related changes in the nematode Caenorhabditis elegans: immunoperoxidase localization of cytokine- and growth factor-like molecules. Eur J Histochem 2003; 47: 75-80.
78. Huising MO, Stet RJ, Savelkoul HF, Verburg-van Kemenade BM. The molecular evolution of the interleukin-1 family of cytokines; IL-18 in teleost fish. Dev Comp Immunol 2004; 28: 395-413.
79. Herpin A, Lelong C, Favrel P. Transforming growth factor-beta-related proteins: an ancestral and widespread superfamily of cytokines in metazoans. Dev Comp Immunol 2004; 28: 461-85.
80. Guayerbas N, Puerto M, Victor VM, Miquel J, De la Fuente M. Leukocyte function and fife span in a routine model of premature immunosenescence. Exp Gerontol 2002; 37: 249-56.
81. Hood L, Galas D. The digital code of DNA. Nature 2003; 421: 444-8.
82. Jeong, H, Tombor B, Albert R, Oltvai ZN, Barabasi AL. The large-scale organization of metabolic networks. Nature 2000; 407: 651-54.
83. Wagner SA, Fell DA. The small world inside large metabolic networks. Proc R Soc London 2001; B268: 1803-10.
84. Jeong H, Mason SP, Barabasi AL, Oltvai ZN. Lethality and centrality in protein networks. Nature 2001; 411: 41-42.
85. Maslov S, Sneppen K. Specificity and stability in topology of protein networks. Science 2002; 296: 910-13.
86. Gavin AC, Bosche M, Krause R, Grandi P, Marzioch M, Bauer A, et al. Functional organization of the yeast proteome by systematic analysis of protein complexes. Nature 2002; 415: 141-7.
87. Milo R, Shen-Orr S, Itzkovitz S, Kashtan N, Chklovskii D, Alon U. Networks motifs: simple building blocks of complex networks. Science 2002; 298: 824-7.
88. Uetz P, Giot L, Cagney G, Mansfield TA, Judson RS, Knight JR, et al. A comprehensive analysis of protein-protein interactions in Saccharomyces cerevisiae. Nature 2000; 403: 623-7.
89. Albert R, Barabasi AL. Statistical Mechanics of Complex Networks. Rev Mod Phys 2002; 74: 47-97.
90. Tieri P, Valensin S, Latora V, Castellani GC, Marchiori M, Remondini D, et al. Quantifying the relevance of different mediators in the human immune cell network. Bioinformatics 2005; 21: 1639-43
91. Abbott A. Growing old gracefully. Nature 2004; 428: 116-8.
92. Kirkwood TB, Franceschi C. Is aging as complex as it would appear? New perspectives in aging research. Ann NY Acad Sci 1992; 663: 412-7.
93. Luciani F, Valensin S, Vescovini R, Sansoni P, Fagnoni F, Franceschi C, et al. A stochastic model for CD8(+)T cell dynamics in human immunosenescence: implications for survival and longevity. J Theor Biol 2001; 213: 587-97.
94. Zanni F, Vescovini R, Biasini C, Fagnoni F, Zanlari L, Telera A, et al. Marked increase with age of type 1 cytokines within memory and effector/ cytotoxic CD8+ T cells in humans: a contribution to understand the relationship between inflammation and immunosenescence. Exp Gerontol 2003; 38: 981-7.
95. Franceschi C, Bonafe M, Valensin S. Human immunosenescence: the prevailing of innate immunity, the failing of clonotypic immunity, and the filling of immunological space. Vaccine 2000; 18: 1717-20.
96. De Martinis M, Modesti M, Ginaldi L. Phenotypic and functional changes of circulating monocytes and polymorphonuclear leucocytes from elderly persons. Immunol Cell Biol 2004; 82: 415-20.
97. Kantardjieff K, Rupp B. Structural bioinformatic approaches to the discovery of new antimycobacterial drugs. Curr Pharm Des 2004; 10(26): 3195-211.
98. Mathis CA, Wang Y, Klunk WE. Imaging beta-amyloid plaques and neurofibrillary tangles in the aging human brain. Curr Pharm Des 2004; 10(13): 1469-92.
99. Thomas M, Le WD. Minocycline: neuroprotective mechanisms in Parkinson's disease. Curr Pharm Des 2004; 10(6): 679-86.